Trial Profile
Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2013
Price :
$35
*
At a glance
- Drugs Cetrorelix (Primary) ; Ganirelix (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Biomarker; Therapeutic Use
- 30 Mar 2012 Planned end date changed from 1 Jun 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 28 Jun 2011 New source identified and integrated (European Clinical Tials Database)
- 06 Jan 2011 New trial record